← SynDRA
TUCATINIB
SynDRA canonical compound SYN0039101 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ERBB2 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
- ERBB2
- EGFR
- ERBB4
- ERBB3
- FECH
- MYH14
- NQO2
- RIPK3
Mechanisms of action (all sources)
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- EGFR INHIBITOR
- ERBB4 INHIBITOR
- ERBB2 MODULATOR
- ERBB3 INHIBITOR
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Cytochrome P450 2C8 Inhibitors
- Cytochrome P450 3A Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- tukysa
- ARRY-380
- ONT-380
- Irbinitinib
- MK-7119
- Tukysa
- ONT 380
- UNII-234248D0HH
- 234248D0HH
- N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine
- 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-
- 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-
- Tucatinib [USAN:INN]
- 6-DIAMINE
- ARRY-380 Analog
- ARRY-380 (analog )
- UNII-H32S1659ED
- HER2 Inhibitor 1
- H32S1659ED
- 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine
- SCHEMBL10169911
- C29H27N7O4S
- DTXSID00239555
- MolPort-023-293-540
- HMS3656B04
- BDBM185146
- EX-A1261
- AOB87708
- BCP02833
- ZINC73096245
- 2227AH
- s2752
- AKOS026750520
- CS-0484
- SB16599
- BCP9000319
- NCGC00346672-01
- NCGC00346672-06
Reported adverse events
- Arthralgia
- Epistaxis
- Nausea
- Rash
- Stomatitis
- Vomiting
- Abdominal pain
- Anxiety
- Back pain
- Chills
- Constipation
- Cough
Look up TUCATINIB in the interactive SynDRA portal →